Standout Papers

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remittin... 2012 2026 2016 2021 868
  1. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial (2012)
    Jeffrey Cohen, Alasdair Coles et al. The Lancet

Immediate Impact

1 from Science/Nature 67 standout
Sub-graph 1 of 22

Citing Papers

Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
2025 Standout
STING orchestrates the neuronal inflammatory stress response in multiple sclerosis
2024 Standout
2 intermediate papers

Works of Bella Ertik being referenced

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
2012 Standout

Author Peers

Author Last Decade Papers Cites
Bella Ertik 747 243 69 287 268 7 913
Cary Twyman 811 279 66 322 294 17 994
M. Stojanovic 806 238 70 358 268 18 1.0k
Peter Alping 751 238 70 337 311 13 913
Pedro Oyuela 923 318 76 360 358 16 1.2k
C. H. Polman 782 153 65 371 249 12 896
Aaron Miller 896 183 88 501 213 5 1.0k
Hadj Benzerdjeb 699 135 81 254 232 6 831
Alexandra Degenhardt 641 99 95 236 133 10 751
J. Deans 607 269 108 298 132 10 978
R. Phillip Kinkel 1021 135 84 569 239 4 1.1k

All Works

Loading papers...

Rankless by CCL
2026